ATNF Key Statistics, Chart & Performance
The current stock price of ATNF is 7.04 USD. In the past month the price increased by 274.47%. In the past year, price increased by 291.11%.
ATNF Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ATNF. When comparing the yearly performance of all stocks, ATNF is one of the better performing stocks in the market, outperforming 99.56% of all stocks.
ATNF Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ATNF. ATNF may be in some trouble as it scores bad on both profitability and health.
ATNF Financial Highlights
Over the last trailing twelve months ATNF reported a non-GAAP Earnings per Share(EPS) of -12.78. The EPS increased by 54.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -160.7% | ||
| ROE | -319.99% | ||
| Debt/Equity | 0.12 |
ATNF Forecast & Estimates
ATNF Ownership
ATNF Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About ATNF
Company Profile
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company is headquartered in Palo Alto, California. The company went IPO on 2017-06-07. The firm is focused on iGaming sector, through its iGaming Technology Platform. The firm also continues to evaluate monetization strategies for its biotechnology assets.
Company Info
180 LIFE SCIENCES CORP
3000 El Camino Real, Bldg 4, Ste 200
Palo Alto CALIFORNIA 10019 US
CEO: James N. Woody
Employees: 4
Phone: 16505070669
180 LIFE SCIENCES CORP / ATNF FAQ
What does 180 LIFE SCIENCES CORP do?
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company is headquartered in Palo Alto, California. The company went IPO on 2017-06-07. The firm is focused on iGaming sector, through its iGaming Technology Platform. The firm also continues to evaluate monetization strategies for its biotechnology assets.
What is the current price of ATNF stock?
The current stock price of ATNF is 7.04 USD. The price decreased by -7.49% in the last trading session.
Does ATNF stock pay dividends?
ATNF does not pay a dividend.
What is the ChartMill rating of 180 LIFE SCIENCES CORP stock?
ATNF has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does 180 LIFE SCIENCES CORP belong to?
180 LIFE SCIENCES CORP (ATNF) operates in the Health Care sector and the Biotechnology industry.
How is the valuation of 180 LIFE SCIENCES CORP (ATNF) based on its PE ratio?
180 LIFE SCIENCES CORP (ATNF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.78).